Invited Commentary
Commentary on "Advice on Stroke Provided by Pharmacies in the United States: Implications for Treatment and Care"
Abstract
The treatment of acute ischemic stroke (AIS) during the past several years has made significant strides with the use of recombinant tissue plasminogen activator (rt-PA). rt-PA is the most readily available treatment for AIS, which can be given in small and large hospitals, and is one of only a limited number of treatment options affording an AIS patient the best chance of reversal of stroke symptoms or minimizing a stroke’s effects. Although the use of rt-PA has increased since its inception, only 3% to 5% of patients with AIS in the United States receive rt-PA.1 The biggest obstacle to more patients being offered rt-PA in AIS is arriving at a facility that is capable of administering the drug within the narrow timeframe from symptom onset. Several variables come into play when attempting to maximize the patient’s recovery potential. The patient and his or her family, emergency medical services (EMS), ancillary medical professionals, and nursing and physicians regardless of specialty must act quickly and in concert for the patient to achieve the best possible outcome.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.